hcv daa therapies in hcv...

SVR

HCV

DAAcirrhosis

HCV

interferon-

DAADAADASVRSVR

G1

oral

tx-naïa veïï

Monday, May 18, 2015Marriott Marquis Washington, DCMarquis Ballroom – Salon 6Level 2

6:00 pm – 6:30 pm Registration and Dinner6:30 pm – 8:30 pm CME-certifi ed Activity

ACTIVITY CHAIR

Ira Jacobson, MD

FACULTY

Andrew Muir, MD, MHS Nancy Reau, MDMark Sulkowski, MD

Strategies for Safe and Efficacious Use of

NEW AND EMERGING THERAPIES IN HCV

This program is not affi liated with Digestive Disease Week®.

This activity is supported by an educational grant from

Gilead Sciences Medical AffairsVINDICOmedical education

This continuing medical education activity is provided by

REGISTER ONLINE! VindicoCME.com/051815

INTERACTIVE CME-CERTIFIED DINNER SYMPOSIUM Introducing SeamlessCME™

A technology platform in which participants will utilize provided iPads to log into the event, respond to assessment and evaluation questions, view all slides, and interact with the faculty.

n

2.0

2015

© iS

tock

phot

o.co

m/B

allu

n; c

arac

terd

esig

n

OVVERVIEWWChronic hepaatitis C viruus (HCV) iinfection iss a leaading causse of cirrhoosis, end-sstage liverr disease, hepatocellular carcinomma, and ddeath from liver diseaase in the United Statess. The disccovery, deevelopmennt, and availability of direct-actiing antiviraal agents (DAAs) offfers new treeatment opttions and tthe possibility of immproved outtcomes forr newly diaagnosed paatients as wwell as thhose who hhave experiienced a relapse or faailed to respond to previous treeatment. WWith the approval of aall-oral, intterferon-free combination therrapies forr HCV treattment, heaalth care pprofessionaals continuue to be challengeed by severral clinicaal questions. In this CCME acttivity, strattegies for tthe safe aand effi caciious use off HCV theerapies, allong with thhe importtance of acchieving suustained viral responsse for imprrovement of hepatic and extrahhepatic maanifestations in mild as well aas severe ddisease, wiill be disscussed. TThe clinicall evidencee regardingg optimal ttreatment duration, moonitoring sttrategies, and drug--drug interaactions forr interferonn-free regimmens willl be reviewwed, along with theeir use in uunique patiient populations.

LEARNING OBJECTIVESUpon successful completion of this educational activity, participants should be better able to:

• Discuss the importance of HCV treatment and achievement of sustained viral response for improvement of hepatic and extrahepatic manifestations, in mild as well as severe disease.

• Apply the clinical evidence to optimize treatment duration, monitoring strategies and drug-drug interactions for newly approved and emerging interferon-free regimens.

• Appraise the clinical evidence to determine how to optimize the use of newly approved and emerging interferon-free regimens in special populations of patients including those with decompensated cirrhosis, HIV/HCV coinfection, transplant/post-transplant of liver, renal Impairment, and HCV genotype 3.

TARGET AUDIENCEThe intended audience for the activity is gastroenterologists, hepatologists, nurse practitioner and physician assistant HCV specialists, and other health care professionals involved in the treatment of patients with HCV.


DADAAAAAA

Introducing SeamlessCME™

A technology platform in which participants will utilize provided iPads to log into the event, respond to assessment and evaluation questions, view all slides, and interact with the faculty.

nt

AGENDA6:30 pm – 6:35 pm Introduction and Pretest Ira Jacobson, MD

6:35 pm – 6:55 pm The Value Proposition of Achieving SVR: Multifaceted Benefi ts & Managing Resource Challenges Nancy Reau, MD

6:55 pm – 7:20 pm Initial Treatment for a Patient with HCV Genotype 1: Considerations for Interferon-Free Treatment Regimens Ira Jacobson, MD

7:20 pm – 7:45 pm Retreatment When Prior Therapy Has Failed Andrew Muir, MD, MHS

7:45 pm – 8:05 pm Key Points for the Use of New HCV Therapies in Distinct Populations Mark Sulkowski, MD

8:05 pm – 8:15 pm Posttest Ira Jacobson, MD

8:15 pm – 8:30 pm Question and Answer Moderated by Ira Jacobson, MD

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

American Academy of Physician Assistants (AAPA) accepts certifi cates of participation for educational activities certifi ed for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hours credit for completing this program.

This educational activity is designed for AMA PRA Category 1 Credit(s)™ for US physicians only. All non-US physicians should contact their respective Boards for accreditation/credit status.

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant fi nancial relationships. Relevant fi nancial relationships will be disclosed to the activity audience.

Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee.

HCV

tx-naïve REGISTER ONLINE! VVindiccoCMME.coom/00518115

SVR

SVSVRR

HCV

DADAAAcirrhohosissis

HCHCCVVV

inintenterferferon-freefree

DDAAADDAAADASVVVRSVVVR

G1G1

oral

tx-tx-naan ïïaa veveïïï

ACTIVITY CHAIRIra Jacobson, MDChairman, Department of MedicineMount Sinai Beth Israel Medical CenterVice Chair of MedicineMount Sinai Health Care SystemSenior Faculty, Icahn School of Medicine at Mount SinaiNew York, NY

FACULTYAndrew Muir, MD, MHS Chief, Division of Gastroenterology Director, GI/Hepatology Research Group Associate Professor of MedicineDepartment of MedicineDuke UniversityDurham, NC

Nancy Reau, MDAssociate Professor of MedicineUniversity of ChicagoChicago, IL

Mark Sulkowski, MDProfessor of Medicine Medical Director of the Viral Hepatitis CenterJohns Hopkins School of MedicineBaltimore, MD


Priority Code: 678 - 1 2 3

Contact Information:E-mail: [email protected]

Toll-free: 877-307-5225, ext. 219 or 476

Phone: 856-994-9400, ext. 219 or 476

Fax: 856-251-0278

Mail: Registration Department 6900 Grove Road Thorofare, NJ 08086-9447

REGISTER ONLINE!VindicoCME.com/051815


ADA compliance: In compliance with the Americans with Disabilities Act of 1990, we will make reasonable efforts to accommodate persons with disabilities. Please call with your requests.

First Name ______________________________ M.I._______ Last Name _________________________________________

Preferred Mailing Address (Home/Business) ___________________________________________________________________

______________________________________________________________________________________________________

City ___________________________ State_______ Zip Code ______________ Country ____________________________

Daytime Phone _______________________________________ Evening Phone ______________________________________

Fax ____________________________ E-mail ______________________________________ Date of Birth _______________

National Provider Identifier (NPI)_______________ Medical License Number______________ Medical License State____________

(for confirmation purposes) (for confirmation purposes) (for tracking credits ONLY)

Hoow did yyou hear about this meetting?(muultiple selectioons allowed)❑ Advertisement ❑ Brochure

❑ E-mail❑ Postcard

❑ Web site❑ Word of mouth

Speecialtty (seelect onee)❑ Gastroenterology❑ Hepatology❑ Infectious Disease❑ Surgery

Degree (please sppecify)❑ MD/DO❑ PhD❑ MD, PhD

❑ Internal Medicine❑ Family Practice/ General Practice

❑ PharmD/RPh❑ PA❑ RN/BSN/MSN

❑ NP❑ Industry❑ Other:_______

CMME Activvity Requuest❑ YES, I would like to receive information regarding future

CME activities related to this therapeutic area.


Strategies for Safe and Efficacious Use of NEW AND EMERGING THERAPIES IN HCV

2.0

INTERACTIVE CME-CERTIFIED DINNER SYMPOSIUM



Strategies for Safe and Efficacious Use of

NEW AND EMERGING THERAPIES IN HCV

INTERACTIVE CME-CERTIFIED DINNER SYMPOSIUM

6900 Grove Road • Building 100Thorofare, NJ 08086-9447

VINDICOmedical education

PresortedFirst Class Mail

US PostagePAID

Permit # 906Bellmawr NJ


2.0

hcv daa therapies in hcv...

Documents